Ordan Mark S's Form 4 filing
Pediatrix Medical Group, Inc.MD · filed Aug 31, 2021
- Accession no.
- 0001209191-21-054168
- Filed
- Aug 31, 2021
- Trade date
- Aug 30, 2021
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $3.33M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ordan Mark SCIK 0001208541 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 30, 2021 | Common Stock | MOption exerciseAcquired | +95,000 | $17.65 | +$1,676,750 | 303,425 | Direct | |
| Aug 30, 2021 | Common Stock | SSaleDisposed | −95,000 | $35.09F2 | −$3,333,550 | 208,425 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 30, 2021 | Common Stock | MOption exerciseDisposed | −95,000 | $17.65 | −$1,676,750 | 455,331 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions with prices ranging from $34.965 to $35.235 for a weighted average sales price of $35.09. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.